Suchergebnisse - "Pinato, David J"

PubPharm (285)

21

Measuring the Invisible : Circulating Tumor DNA as a Predictive and Prognostic Marker of Response to Adjuvant Chemotherapy in Resected Colorectal Cancer

enthalten in: Gastroenterology | 2023

von D'Arienzo, P. | Pinato, D.

22

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy : A global, observational study

enthalten in: Hepatology communications | 2023

von Joerg, V. | Scheiner, B. | D Alessio, A. | +33

23

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors : Impact on Efficacy and Survival

enthalten in: Cancers | 2023

von Choucair, K. | Nebhan, C. | Cortellini, A. | +23

24

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

enthalten in: Journal for immunotherapy of cancer | 2023

von Naqash, A. | McCallen, J. | Mi, E. | +22

25

Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC) : "Real World" Experience

enthalten in: Clinical genitourinary cancer | 2023

von Bakaloudi, D. | Talukder, R. | Lin, G. | +32

26

Diabetes and Immune Checkpoint Inhibitors-Response

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Cortellini, A. | D'Alessio, A. | Pinato, D.

CommentOn: Clin Cancer Res. 2023 Jul 14;29(14):2714-2724. - PMID 37125965

27

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma : A Systematic Review and Meta-Analysis

enthalten in: JAMA oncology | 2023

von Xie, E. | Yeo, Y. | Scheiner, B. | +25

28

Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy

enthalten in: Hepatology communications | 2023

von Scheiner, B. | Lampichler, K. | Pomej, K. | +13

29

The price and value of therapeutic synergy in liver cancer

enthalten in: Lancet (London, England) | 2023

von Pinato, D. | D'Alessio, A. | Celsa, C. | +2

CommentOn: Lancet. 2023 Sep 30;402(10408):1133-1146. - PMID 37499670

30

Immune checkpoint inhibitors in hepatocellular carcinoma : emerging challenges in clinical practice

enthalten in: The lancet. Gastroenterology & hepatology | 2023

von Pinter, M. | Scheiner, B. | Pinato, D.